Roivant Sciences Ltd (NAS:ROIV)
$ 12.71 0.02 (0.16%) Market Cap: 9.25 Bil Enterprise Value: 3.92 Bil PE Ratio: 2.25 PB Ratio: 1.81 GF Score: 61/100

Roivant Sciences Ltd at Guggenheim Securities Inflammation & Immunology Conference Transcript

Nov 07, 2023 / 09:30PM GMT
Release Date Price: $9.09 (+2.25%)
Yatin Suneja
Guggenheim Securities, LLC, Research Division - Senior MD & Equity Research Analyst

Good afternoon, everyone. My name is Yatin Suneja. I'm one of the biotech analysts here at Guggenheim. It is my pleasure to welcome all of you to our 5th Annual I&I Conference. This is day 2. And our next presenting company is Roivant.

From the company -- we have a couple of executives from the company here in our room, but I'm going to be chatting here with the Chief Executive Officer, Matthew Gline.

Matthew or Matt, why don't you maybe kick us off, make some opening comments, tell us what's going on at Roivant, what are some of the up-and-coming milestone that we should be focusing on? And then we'll go into a little bit more of a fireside session after that. Matt?

Matthew Gline
Roivant Sciences Ltd. - CEO & Director

Perfect. Yes. Thank you. Thanks for having us. Thanks, Guggenheim. It's a great privilege to participate in the conference. And obviously, thanks for all the great coverage as well. It's exciting to be here.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot